Gene therapy for haemophilia...yes, but...with non-viral vectors?

Abstract

High-purity plasma-derived and recombinant factors are currently safe and efficient treatment for haemophilia. The mid-term future of haemophilia treatment will involve the use of modified recombinant factors to achieve advantages such as decreased immunogenicity in inhibitor formation and enhanced efficacy as a result of their longer half-life. In the long… (More)
DOI: 10.1111/j.1365-2516.2009.02010.x

Topics

  • Presentations referencing similar topics